Cadrenal Therapeutics, Inc. rose 39.8% on Monday, November 9, 2026, on 370,354 shares. No headline about CVKD came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Cadrenal Therapeutics, Inc. (CVKD:NASDAQ) closed at $1.37 on November 9, 2026, up 39.80% on the day. The stock trades 89.5% below its 52-week high of $13.01 and 67.9% above its 52-week low of $0.816. Over the past year, it lost 88.9%. Cadrenal Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since November 7, 2025, CVKD closed higher on 96 days (38%). Its best day was November 9, 2026 (+39.80%) and its worst was December 16, 2025 (-32.87%). The stock moved 10% or more in a single session 28 times. It opened at least 5% above the previous day's high 3 times.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Find more stocks like CVKD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.